October 2, 2001

Sonus Pharmaceuticals To Release Third Quarter Financial Results And Hold Quarterly Conference Call On October 9, 2001

BOTHELL, Washington, October 2, 2001-Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) announced today that it will release financial results for the third quarter and provide a company update during its quarterly conference call on October 9, 2001.

The conference call will be held at 1:30 P.M. PDT, 4:30 P.M. EDT. To access the conference call via live webcast, visit Sonus' web site at www.sonuspharma.com/investor.html (under calendar of events). The webcast will be archived on the Company's web site for approximately one week following the live broadcast.

Sonus Pharmaceuticals, Inc., located near Seattle, Washington, is engaged in the research and development of therapeutic drug delivery products based on its proprietary emulsion formulation technology. The Company's lead product is S-8184, a new formulation of paclitaxel for cancer therapy, which is currently in a Phase 1 clinical study. In preclinical development, Sonus is also developing S-2646, a reformulation of amiodarone, a cardiac drug for the treatment of rapid, life-threatening heart rhythms; and S-9156, an oxygen delivery product.

The Company's news releases and other corporate information are available on its web site at www.sonuspharma.com.

Contact: Pamela Dull, Sonus Pharmaceuticals, Inc. (425) 487-9500.

Close window | Back to top

Copyright 2018 OncoGenex Pharmaceuticals, Inc.